BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12494937)

  • 1. Voriconazole versus amphotericin B for invasive aspergillosis.
    Karthaus M
    N Engl J Med; 2002 Dec; 347(25):2080-1; author reply 2080-1. PubMed ID: 12494937
    [No Abstract]   [Full Text] [Related]  

  • 2. Voriconazole versus amphotericin B for invasive aspergillosis.
    Blot F; Edé C; Nitenberg GM
    N Engl J Med; 2002 Dec; 347(25):2080-1; author reply 2080-1. PubMed ID: 12490695
    [No Abstract]   [Full Text] [Related]  

  • 3. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
    Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
    Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
    Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis.
    Kirkpatrick WR; Coco BJ; Patterson TF
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1567-9. PubMed ID: 16569887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
    Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
    N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving the outcome of invasive aspergillosis: new diagnostic tools and new therapeutic strategies.
    Herbrecht R
    Ann Hematol; 2002; 81 Suppl 2():S52-3. PubMed ID: 12611078
    [No Abstract]   [Full Text] [Related]  

  • 8. Voriconazole.
    Med Lett Drugs Ther; 2002 Jul; 44(1135):63-5. PubMed ID: 12138377
    [No Abstract]   [Full Text] [Related]  

  • 9. An unusual case of pulmonary invasive aspergillosis and aspergilloma cured with voriconazole in a patient with cystic fibrosis.
    Chow L; Brown NE; Kunimoto D
    Clin Infect Dis; 2002 Nov; 35(9):e106-10. PubMed ID: 12384856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis.
    Chandrasekar PH; Cutright JL; Manavathu EK
    Clin Microbiol Infect; 2004 Oct; 10(10):925-8. PubMed ID: 15373889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful management of invasive aspergillosis with voriconazole and amphoteracin B therapy in a patient with acute mycloid leukemia (AML-M2).
    Manzoor NF; Azim S; Fadoo Z
    J Pak Med Assoc; 2010 Nov; 60(11):977-9. PubMed ID: 21375212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients.
    Wenzel R; Del Favero A; Kibbler C; Rogers T; Rotstein C; Mauskopf J; Morris S; Schlamm H; Troke P; Marciniak A
    J Antimicrob Chemother; 2005 Mar; 55(3):352-61. PubMed ID: 15728146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of brain aspergillosis with voriconazole.
    Tattevin P; Bruneel F; Lellouche F; de Broucker T; Chevret S; Wolff M; Régnier B
    Clin Microbiol Infect; 2004 Oct; 10(10):928-31. PubMed ID: 15373890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight.
    Frankenbusch K; Eifinger F; Kribs A; Rengelshauseu J; Roth B
    J Perinatol; 2006 Aug; 26(8):511-4. PubMed ID: 16871222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.
    Wingard JR; Herbrecht R; Mauskopf J; Schlamm HT; Marciniak A; Roberts CS
    Transpl Infect Dis; 2007 Sep; 9(3):182-8. PubMed ID: 17605747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant endobronchial amphotericin B for refractory invasive pulmonary aspergillosis: evidence is scarce but promise does exist.
    Stratakos G; Zakynthinos S
    Respiration; 2007; 74(6):609-10. PubMed ID: 18037812
    [No Abstract]   [Full Text] [Related]  

  • 17. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
    Sambatakou H; Dupont B; Lode H; Denning DW
    Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.
    Santos RP; Sánchez PJ; Mejias A; Benjamin DK; Walsh TJ; Patel S; Jafri HS
    Pediatr Infect Dis J; 2007 Apr; 26(4):364-6. PubMed ID: 17414408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experience with voriconazole in invasive aspergillosis].
    Thiel E; Schwartz S
    Mycoses; 2003; 46 Suppl 2():3-7. PubMed ID: 15055137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical voriconazole solution for cutaneous aspergillosis in a pediatric patient after bone marrow transplant.
    Klein KC; Blackwood RA
    Pediatrics; 2006 Aug; 118(2):e506-8. PubMed ID: 16816005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.